Updates are available Correction dated 2025-08-20
Click to view Correction: https://doi.org/10.1038/s41598-025-16245-5
-
Authors
Salako, Abideen
Musa, Adesola
Ige, Fehintola
Abdullahi, Adam
James, Ayorinde
Ekama, Sabdat
Odubela, Oluwatosin
Idigbe, Ifeoma
Ajibaye, Olusola
Altaf, Mazharul
Adeneye, Kazeem
Akinsolu, Folahanmi T.
Olojo, Ifedola
Okwuraiwe, Azuka
Egharevba, Henry
Ekpenyong, Magaret
Elemuwa, Uchenna
Ezenyi, Ifeoma
Bitrus, Fraden
Odubela, Olayemi
Oba, Abdulrasheed
Idris, Ganiu
Yusuf, Jimoh
Akande, Ibukun
Nwaiwu, Stephine
Omale, Louisa
Oyewunmi, Oluwatobiloba
Agbabiaka, Adedoyin
Eyinade, Olajumoke
Ogunwale, Joy
Garba, Abdullah
Bello, Yahya
Musa, Baba
Ezejiofor, Ogochukwu
Ejiro, Ben
Iwalokun, Bamidele
Rosenzweig, Leah
Adigwe, Obi
Adeyeye, Christianah
Shuaib, Faisal
Wicek, Witold
Hamada, Yohhei
Ezechi, Oliver
Gupta, Ravindra
Salako, Babatunde
-
Clinical Trials BETA
Clinical trials referenced in this document:
pactr202206754734018 at Pan African Clinical Trial RegistryDocuments that mention this clinical trial
Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial
https://doi.org/10.1038/s41598-025-06536-2
-
Funding
Funding for this research was provided by:
Open Philanth
Wellcome Trust (WT108082AIA)
- License Information
-
More Information
Article History
Received: 12 December 2024
Accepted: 9 June 2025
First Online: 29 July 2025
Change Date: 20 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-16245-5
Declarations
:
: The authors declare no competing interests.
: All procedures performed in studies involving human participants were following the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Ethical approval was obtained from the National Health Research and Ethics Committee, the Institutional Review Board (IRB) of NIMR, Lagos, and the ethics committee of the trial institution. The purpose, processes, and expected outcome of the study were explained to all participants and/or their caregivers and informed consent was obtained before the commencement of the study. Confidentiality was maintained, and the freedom to withdraw at any time from the study without negative consequences was emphasized.
